Transfusion independence and HMGA2 activation after gene therapy of human β-thalassaemia
Open accessThe DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Abstract
The β-haemoglobinopathies are the most prevalent inherited disorders worldwide. Gene therapy of β-thalassaemia is particularly challenging given the requirement for massive haemoglobin production in a lineage-specific manner and the lack of selective advantage for corrected haematopoietic stem cells. Compound βE/β0-thalassaemia is the most common form of severe thalassaemia in southeast Asian countries and their diasporas. The βE-globin allele bears a point mutation that causes alternative splicing. The abnormally spliced form is non-coding, whereas the correctly spliced messenger RNA expresses a mutated βE-globin with partial instability. When this is compounded with a non-functional β0 allele, a profound decrease in β-globin synthesis results, and approximately half of βE/β0-thalassaemia patients are transfusion-dependent. The only available curative therapy is allogeneic haematopoietic stem cell transplantation, although most patients do not have a human-leukocyte-antigen-matched, geno-identical donor, and those who do still risk rejection or graft-versus-host disease. Here we show that, 33 months after lentiviral β-globin gene transfer, an adult patient with severe βE/β0-thalassaemia dependent on monthly transfusions since early childhood has become transfusion independent for the past 21 months. Blood haemoglobin is maintained between 9 and 10 g dl−1, of which one-third contains vector-encoded β-globin. Most of the therapeutic benefit results from a dominant, myeloid-bia…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Interestingly, this response was associated with a relative increase in a dominant myeloid clone bearing a lentiviral vector insertion within the HMGA2 gene locus.”
From Clinical use of lentiviral vectors (2018) · cites this paper as [67]
In the citing paper
“In the initial study of HSCs transduced with β-globin in patients with β-thalassemia, one patient with βE/β0-thalassemia achieved independence from transfusion [67].”
From Clinical use of lentiviral vectors (2018) · cites this paper as [67]
In the citing paper
“Lentiviral vector-based gene transfer into CD34 + HSCs has subsequently been applied in the treatment of several genetic diseases, including β-thalassemia [67], X-linked adrenoleukodystrophy [51], metachromatic leukodystrophy [68, 69], and Wiskott-Aldrich Syndrome [70].”
From Clinical use of lentiviral vectors (2018) · cites this paper as [67]
In the citing paper
“The relative clonal dominance at the HMGA2 locus that was initially observed in 1 patient in the LG001 study of the HPV569 vector spontaneously subsided while that patient maintained stable HbA T87Q levels.”
From Gene Therapy in Patients with Transfusion-Dependent β-Thalassemia (2018) · cites this paper as [20]
In the citing paper
“The feasibility of the addition of a gene to autologous hematopoietic cells using a lentiviral vector was shown previously in a single patient with β-thalassemia who safely discontinued transfusions for more than 6 years with ongoing, sustained β A-T87Q -globin expression.14,20”
From Gene Therapy in Patients with Transfusion-Dependent β-Thalassemia (2018) · cites this paper as [20]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
MicroRNA maturation: stepwise processing and subcellular localization
Lee, Y. (2002) · The EMBO Journal · doi:10.1093/emboj/cdf476 · Cited by 2,478
Position-independent, high-level expression of the human β-globin gene in transgenic mice
Grosveld, F., van Assendelft, G. B., Greaves, D. R., & Kollias, G. (1987) · Cell · doi:10.1016/0092-8674(87)90584-8 · Cited by 1,909 · cited 1×
“To demonstrate that only one integrated vector provirus was present in cells with the HMGA2 IS, three qPCR experiments were simultaneously performed on the same genomic DNA preparation with primers specific for either (1) a ‘HIV gag packaging signal’ DNA sequence (common to all vector provirus regardless of IS); (2) t…”
MethodInsertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1
Hacein-Bey-Abina, S., Garrigue, A., Wang, G. P., Soulier, J., Lim, A., Morillon, E., Clappier, E., Caccavelli, L., Delabesse, E., Beldjord, K., et al. (2008) · Journal of Clinical Investigation · doi:10.1172/jci35700 · Cited by 1,854
Self-citationHematopoietic Stem Cell Gene Therapy with a Lentiviral Vector in X-Linked Adrenoleukodystrophy
Cartier, N., Hacein-Bey-Abina, S., Bartholomae, C. C., Veres, G., Schmidt, M., Kutschera, I., Vidaud, M., Abel, U., Dal-Cortivo, L., Caccavelli, L., et al. (2009) · Science · doi:10.1126/science.1171242 · Cited by 1,508
Self-citationOtt, M. G., Schmidt, M., Schwarzwaelder, K., Stein, S., Siler, U., Koehl, U., Glimm, H., Kühlcke, K., Schilz, A., Kunkel, H., et al. (2006) · Nature Medicine · doi:10.1038/nm1393 · Cited by 1,051
Chung, J. H., Whiteley, M., & Felsenfeld, G. (1993) · Cell · doi:10.1016/0092-8674(93)80052-g · Cited by 854
Lin28 promotes transformation and is associated with advanced human malignancies
Viswanathan, S. R., Powers, J. T., Einhorn, W., Hoshida, Y., Ng, T. L., Toffanin, S., O'Sullivan, M., Lu, J., Phillips, L. A., Lockhart, V. L., et al. (2009) · Nature Genetics · doi:10.1038/ng.392 · Cited by 814
Long-Term Propagation of Distinct Hematopoietic Differentiation Programs In Vivo
Dykstra, B., Kent, D., Bowie, M., McCaffrey, L., Hamilton, M., Lyons, K., Lee, S.-J., Brinkman, R., & Eaves, C. (2007) · Cell Stem Cell · doi:10.1016/j.stem.2007.05.015 · Cited by 609
Correction of sickle cell disease in transgenic mouse models by gene therapy
Pawliuk, R., Westerman, K. A., Fabry, M. E., Payen, E., Tighe, R., Bouhassira, E. E., Acharya, S. A., Ellis, J., London, I. M., Eaves, C. J., et al. (2001) · Science · doi:10.1126/science.1065806 · Cited by 579
Self-citationMay, C., Rivella, S., Callegari, J., Heller, G., Gaensler, K. M. L., Luzzatto, L., & Sadelain, M. (2000) · Nature · doi:10.1038/35017565 · Cited by 567 · cited 1×
“Numbers along the top indicate blood progenitors from a b-thalassaemic control individual (1), patient P2’s blood progenitors 27 months posttransplantation showing a band consistent with truncated fusion protein of 135 amino acids (2), recombinant truncated (73 amino acids) (4) and fulllength (109 amino acids) (5) hum…”
Background
Cited by
Items 501–600 of 1,000
Enhancing the purification of Lentiviral vectors for clinical applications
Moreira, A. S., Faria, T. Q., Oliveira, J. G., Kavara, A., Schofield, M., Sanderson, T., Collins, M., Gantier, R., Alves, P. M., Carrondo, M. J. T., et al. (2021) · Separation and Purification Technology · doi:10.1016/j.seppur.2021.118598 · Cited by 29
The transformative potential of HSC gene therapy as a genetic medicine
Sagoo, P., & Gaspar, H. B. (2021) · Gene Therapy · doi:10.1038/s41434-021-00261-x · Cited by 28
“HSC gene therapy treatments Since the first clinical trials with LV-mediated HSC GT in the mid-2000s [67, 68], this approach has now been employed safely and effectively across numerous different primary immune deficiencies, hemoglobinopathies, and storage and metabolic diseases, providing proof of its transformative…”
BackgroundComisel, R.-M., Kara, B., Fiesser, F. H., & Farid, S. S. (2021) · Biochemical Engineering Journal · doi:10.1016/j.bej.2021.108202 · Cited by 28
Updates and advances in pyruvate kinase deficiency
Luke, N., Hillier, K., Al-Samkari, H. T., & Grace, R. F. (2023) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2023.02.005 · Cited by 27
The potential for tumor suppressor gene therapy in head and neck cancer.
Birkeland, A. C., Ludwig, M., Spector, M. E., & Brenner, J. C. (2016) · PubMed · Cited by 30
Promise of gene therapy to treat sickle cell disease
Romero, Z. G., DeWitt, M. A., & Walters, M. C. (2018) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2018.1536119 · Cited by 29
“An amino-acid modification at codon 87 of the β-globin gene that had anti-sickling activity and mimicked the anti-sickling effect of HbF (HPV 569) [54] was first introduced and tested in a clinical trial in France in 2006 [55], in which a patient with E-β° thalassemia who was transfusion-dependent, was able to stop tr…”
MethodMetabolic Correction of Congenital Erythropoietic Porphyria with iPSCs Free of Reprogramming Factors
Bedel, A., Taillepierre, M., Guyonnet‐Dupérat, V., Lippert, É., Dubus, P. R., Dabernat, S., Mautuit, T., Cardinaud, B., Pain, C., Rousseau, B., et al. (2012) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2012.05.026 · Cited by 27
Novel gene manipulation approaches to unlock the existing bottlenecks of CAR-NK cell therapy
Dehghan, F., Metanat, Y., Askarizadeh, M., Ahmadi, E., & Moradi, V. (2025) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2024.1511931 · Cited by 29
Ball, J., Bradley, A., Le, A., Tisdale, J. F., & Uchida, N. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.03.016 · Cited by 31
Cornils, K., Bartholomae, C. C., Thielecke, L., Lange, C., Arens, A., Glauche, I., Mock, U., Riecken, K., Gerdes, S., Kalle, C. V., et al. (2012) · Experimental Hematology · doi:10.1016/j.exphem.2012.09.003 · Cited by 28
Induced pluripotent stem cells in hematology: current and future applications
Focosi, D., Amabile, G., Ruscio, A. D., Quaranta, P., Tenen, D. G., & Pistello, M. (2014) · Blood Cancer Journal · doi:10.1038/bcj.2014.30 · Cited by 28
Bustamante, O. Q., Fañanas-Baquero, S., Orman, I., Torres-Ruiz, R., Duchateau, P. N., Poirot, L., Gouble, A., Bueren, J. A., & Segovia, J. C. (2019) · PLoS ONE · doi:10.1371/journal.pone.0223775 · Cited by 26
Rattananon, P., Anurathapan, U., Bhukhai, K., & Hongeng, S. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.730873 · Cited by 31
Optimization of Magnetic Nanoparticle-Assisted Lentiviral Gene Transfer
Trueck, C., Zimmermann, K., Mykhaylyk, O. M., Anton, M., Vosen, S., Wenzel, D., Fleischmann, B. K., & Pfeifer, A. (2012) · Pharmaceutical Research · doi:10.1007/s11095-011-0660-x · Cited by 26
Meng, X., Baylink, D. J., Sheng, M. H. ‐., Wang, H., Gridley, D. S., Lau, K. ‐. W., & Zhang, X. (2012) · PLoS ONE · doi:10.1371/journal.pone.0037569 · Cited by 26
“used in stem cell gene therapy for treating red blood cell (RBC) diseases [17,18].”
BackgroundIn vivo activation of the human -globin gene: the therapeutic potential in -thalassemic mice
Manchinu, M. F., Marongiu, M. F., Poddie, D., Casu, C., Latini, V., Simbula, M., Galanello, R., Moi, P., Cao, A., Porcu, S., et al. (2013) · Haematologica · doi:10.3324/haematol.2012.082768 · Cited by 28
“which could be a harbinger of a leukemic transformation as seen previously in gene therapy protocols with retroviruses.(24,25) Another important line of research for the treatment of βthalassemia and SCD is the activation of the g-globin gene, not normally expressed in adults, although success with this strategy had b…”
BackgroundSelf-inactivating MLV vectors have a reduced genotoxic profile in human epidermal keratinocytes
Cavazza, A., Cocchiarella, F., Bartholomae, C. C., Schmidt, M., Pincelli, C., Larcher, F., & Mavilio, F. (2013) · Gene Therapy · doi:10.1038/gt.2013.18 · Cited by 27
Brendel, C., Haenseler, W., Wohlgensinger, V., Bianchi, M., Tokmak, S., Chen-Wichmann, L., Kuzmenko, E. S., Cesarovic, N., Nicholls, F., Reichenbach, J., et al. (2013) · Human Gene Therapy Methods · doi:10.1089/hgtb.2012.157 · Cited by 27
“…benefit for treated patients has been continuously growing (Aiuti et al. , 2002; Mavilio et al. , 2006; Morgan et al. , 2006; Ott et al. , 2006; Kaplitt et al. , 2007; Bainbridge et al. , 2008; Cartier et al. , 2009; Boztug et al. , 2010; Cavazzana-Calvo et al. , 2010; Porter et al. , 2011).”
Cannon, P. M., Asokan, A., Czechowicz, A. D., Hammond, P. T., Kohn, D. B., Lieber, A., Malik, P., Marks, P. W., Porteus, M. H., Verhoeyen, E., et al. (2021) · Human Gene Therapy · doi:10.1089/hum.2020.263 · Cited by 29
“This vector was successful in only one of three patients after autologous transplantation after myeloablative busulfan conditioning.(8) Thereafter, an improved version of b(87)/HVP569 that had no insulator and an improved titer, the LentiGlobin vector, showed success in thalassemia major patients with less severe thal…”
BackgroundNéri, T., Muggeo, S., Paulis, M., Caldana, M. E., Crisafulli, L., Strina, D., Focarelli, M. L., Faggioli, F., Recordati, C., Scaramuzza, S., et al. (2015) · Stem Cell Reports · doi:10.1016/j.stemcr.2015.08.005 · Cited by 27
“HSC gene therapy is being utilized with efficacy in a number of genetic diseases (Aiuti et al., 2009, 2013; Biffi et al., 2013; Cavazzana-Calvo et al., 2010; Hacein-Bey-Abina et al., 2010).”
MethodLidonnici, M. R., Paleari, Y., Tiboni, F., Mandelli, G., Rossi, C., Vezzoli, M., Aprile, A., Lederer, C. W., Ambrosi, A., Chanut, F. J.-A., et al. (2018) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2018.09.001 · Cited by 26
“Non-clinical studies showed that LVs are less likely to cause insertional gene activation than retroviral vectors,(17) although they can still cause interference with normal gene regulation by inducing alterations in transcriptional activity, aberrant splicing,(22,23) and premature transcript termination, as observed…”
Leboulch, P. (2013) · Nature · doi:10.1038/500280a · Cited by 27
Self-citationThe GATA1-HS2 Enhancer Allows Persistent and Position-Independent Expression of a β-globin Transgene
Miccio, A., Poletti, V., Tiboni, F., Rossi, C., Antonelli, A., Mavilio, F., & Ferrari, G. (2011) · PLoS ONE · doi:10.1371/journal.pone.0027955 · Cited by 28
“Chromatin insulators, such as the cHS4 element, reduce only partially positional effects, while affecting both titer and genetic stability of the vectors [7,10,11].”
BackgroundLentiviral Transduction of CD34+ Cells Induces Genome-Wide Epigenetic Modifications
Yamagata, Y., Parietti, V., Stockholm, D., Corre, G., Poinsignon, C., Touleimat, N., Delafoy, D., Besse, C., Tost, J., Galy, A. H. M., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0048943 · Cited by 27
“mia [31,32,33,34].”
Genetic Engineering and Manufacturing of Hematopoietic Stem Cells
Wang, X., & Rivière, I. (2017) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2017.03.003 · Cited by 28
“Importantly, this clone never progressed to leukemia.(60) In-depth molecular analysis of the reconstituted hematopoiesis in patients with various diseases and treated with different types of vectors has allowed the characterization of vector-insertion distribution.”
BackgroundAllogeneic/Matched Related Transplantation for β-Thalassemia and Sickle Cell Anemia
Bernaudin, F., Pondarré, C., Galambrun, C., & Thuret, I. (2017) · Advances in experimental medicine and biology · doi:10.1007/978-1-4939-7299-9_4 · Cited by 29
Self-citationUchida, N., Haro‐Mora, J. J., Demirci, S., Fujita, A., Raines, L. N., Hsieh, M. M., & Tisdale, J. F. (2018) · Experimental Hematology · doi:10.1016/j.exphem.2018.02.007 · Cited by 29
Preclinical Development of Cell-Based Products: a European Regulatory Science Perspective
McBlane, J. W., Phul, P., & Sharpe, M. E. (2018) · Pharmaceutical Research · doi:10.1007/s11095-018-2437-y · Cited by 27
Poletti, V., Urbinati, F., Charrier, S., Corre, G., Hollis, R. P., Fernandez, B. C., Martin, S., Rothe, M., Schambach, A., Kohn, D. B., et al. (2018) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2018.10.014 · Cited by 27
“SCD is therefore a more demanding context with respect to b-thalassemia, where substantial clinical benefit has been achieved with the current b-globin vectors.(13,24,25) Innovation in vector design, HSC procurement, cell manufacturing, and conditioning regimens appear necessary to achieve the efficacy required to cur…”
BackgroundTranscriptional Targeting and MicroRNA Regulation of Lentiviral Vectors
Merlin, S., & Follenzi, A. (2019) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2018.12.013 · Cited by 25
“The design of the LV for human b-globin gene therapy, to achieve high and erythroid-specific expression, requires not only the b-globin gene containing a mutation (b) with anti-sickling properties, but also b-globin gene introns, promoter, enhancers, and b-locus control region (b-LCR).(74,75) Phase 1/2 and phase 3 stu…”
MethodCURING HEMOGLOBINOPATHIES: CHALLENGES AND ADVANCES OF CONVENTIONAL AND NEW GENE THERAPY APPROACHES.
Motta, I., Ghiaccio, V., Cosentino, A., & Breda, L. (2019) · Mediterranean Journal of Hematology and Infectious Diseases · doi:10.4084/mjhid.2019.067 · Cited by 26
Photothermal Intracellular Delivery Using Gold Nanodisk Arrays
Zhao, C., Man, T., Xu, X., Yang, Q., Liu, W., Jonas, S. J., Teitell, M. A., Chiou, P.-Y. E., & Weiss, P. S. (2020) · ACS Materials Letters · doi:10.1021/acsmaterialslett.0c00428 · Cited by 25
Pulmonary gene delivery—Realities and possibilities
Baliga, U. K., & Dean, D. A. (2020) · Experimental Biology and Medicine · doi:10.1177/1535370220965985 · Cited by 25
“Specific examples of this transplant approach include Duchenne muscular dystrophy,(53) leukodystrophies,(57,58) and beta-thalassemia.(59) Lentiviral vectors have also been used effectively for gene transfer directly in the lung, primarily in small animal models.”
Oikonomopoulou, C., & Goussetis, E. (2021) · Bone Marrow Transplantation · doi:10.1038/s41409-021-01461-0 · Cited by 26
Papanikolaou, E., Georgomanoli, M., Stamateris, E., Panetsos, F., Karagiorga, M., Tsaftaridis, P., Graphakos, S., & Anagnou, N. P. (2011) · Human Gene Therapy · doi:10.1089/hum.2011.048 · Cited by 25
“Similarly, in the paper describing the first clinical trial for thalassemia gene therapy by the Leboulch group (Cavazzana-Calvo et al., 2010) it is documented that exogenous b-globin accounts for one-third of total hemoglobin in a patient who had been transfusion independent for more than 1 year.”
InfluentialPeng, M., Rayana, N. P., Dai, J., Sugali, C. K., Baidouri, H., Suresh, A., Raghunathan, V. K., & Mao, W. (2022) · Experimental Eye Research · doi:10.1016/j.exer.2022.109097 · Cited by 24
Murphy, L. A., Marians, R. C., Miller, K. R., Brenton, M. D., Mallo, R., Kohler, M. E., Fry, T. J., & Winters, A. C. (2022) · Cytotherapy · doi:10.1016/j.jcyt.2022.09.004 · Cited by 24
miRNA Pathway Alteration in Response to Non-Coding RNA Delivery in Viral Vector-Based Gene Therapy
Savenkova, D. A., Makarova, A.-L. A., Shalik, I. K., & Yudkin, D. V. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232314954 · Cited by 26
Sitaraman, V., Hearing, P., Ward, C. B., Gnatenko, D. V., Wimmer, E., Mueller, S., Skiena, S., & Bahou, W. F. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1102883108 · Cited by 26
“Insertional mutagenesis remains a fundamental concern for long-term gene replacement strategies (37, 38) and for genetic reprogramming of pluripotent stem cells (39).”
BackgroundGene Therapy and Genome Editing
Boulad, F., Mansilla‐Soto, J., Cabriolu, A., Rivière, I., & Sadelain, M. (2018) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2017.11.007 · Cited by 24
Hematopoietic Stem Cell Gene Therapy for Brain Metastases Using Myeloid Cell–Specific Gene Promoters
Andreou, T., Rippaus, N., Wronski, K., Williams, J. M., Taggart, D., Cherqui, S., Sunderland, A., Kartika, Y. D., Egnuni, T., Brownlie, R. J., et al. (2019) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djz181 · Cited by 27
Experimental gene transfer to the corneal endothelium
Kampik, D., Ali, R. R., & Larkin, F. (2011) · Experimental Eye Research · doi:10.1016/j.exer.2011.07.001 · Cited by 26
Vranckx, L. S., Demeulemeester, J., Debyser, Z., & Gijsbers, R. (2016) · PLoS ONE · doi:10.1371/journal.pone.0164167 · Cited by 24
Candidate Diseases for Prenatal Gene Therapy
David, A. L., & Waddington, S. N. (2012) · Humana Press eBooks · doi:10.1007/978-1-61779-873-3_2 · Cited by 26
Gene Therapy Through Autologous Transplantation of Gene-Modified Hematopoietic Stem Cells
Kohn, D. B., Pai, S., & Sadelain, M. (2012) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2012.09.021 · Cited by 26
Wang, Y.-C., Wu, Y., Choi, J. Y., Allington, G., Zhao, S., Khanfar, M., Yang, K., Fu, P.-Y., Wrubel, M., Yu, X., et al. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12020175 · Cited by 25
Brusson, M., Chalumeau, A., Martinucci, P., Romano, O., Félix, T., Poletti, V., Scaramuzza, S., Ramadier, S., Masson, C., Ferrari, G., et al. (2023) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2023.03.012 · Cited by 25
Ex Vivo Gene Therapy and Vision
Gregory-Evans, K., Bashar, E., & Tan, M. (2012) · Current Gene Therapy · doi:10.2174/156652312800099607 · Cited by 24
Barese, C. N., Krouse, A. E., Metzger, M. E., King, C. A., Traversari, C., Marini, F. C., Donahue, R. E., & Dunbar, C. E. (2012) · Molecular Therapy · doi:10.1038/mt.2012.166 · Cited by 28
Brugman, M. H., Suerth, J. D., Rothe, M., Suerbaum, S., Schambach, A., Modlich, U., Kustikova, O. S., & Baum, C. (2013) · Human Gene Therapy Methods · doi:10.1089/hgtb.2012.175 · Cited by 23
“Experimental (Cornils et al., 2013) as well as clinical studies (Cartier et al., 2009; Boztug et al., 2010; Cavazzana-Calvo et al., 2010; Wang et al., 2010) have used the number of reads acquired from deep sequencing experiments as a quantitative measure of abundance.”
BackgroundIntegration Site and Clonal Expansion in Human Chronic Retroviral Infection and Gene Therapy
Niederer, H. A., & Bangham, C. R. M. (2014) · Viruses · doi:10.3390/v6114140 · Cited by 24
“Recently, HIV-based self-inactivating vectors have been used in a number of trials [27–30].”
MethodUchida, N., Hanawa, H., Yamamoto, M., & Shimada, T. (2013) · Human Gene Therapy Methods · doi:10.1089/hgtb.2012.152 · Cited by 23
Gene transfer into hematopoietic stem cells as treatment for primary immunodeficiency diseases
Candotti, F. (2014) · International Journal of Hematology · doi:10.1007/s12185-014-1524-z · Cited by 25
“As anticipated, the notions gathered by the early experimentations in PIDs have posed the bases for extending gene correction procedures to more frequent genetic disorders of hematopoiesis, such as thalassemia [3], and are expected to be applied in the near future to a variety of common disease, including malignancies…”
Stein, S., Scholz, S., Schwäble, J., Sadat, M., Modlich, U., Schultze‐Strasser, S., Diaz, M., Chen-Wichmann, L., Müller-Kuller, U., Brendel, C., et al. (2013) · Human Gene Therapy Clinical Development · doi:10.1089/humc.2013.019 · Cited by 28
“…Diez et al., 2011; Huston et al., 2011; Tolar et al., 2012; Scaramuzza et al., 2013) and ongoing clinical trials, although the follow-up time of treated patients is still too short to make conclusive statements at present (Cartier et al., 2009; Cavazzana-Calvo et al., 2010; Biffi et al., 2011).”
Dighe, N., Khoury, M., Mattar, C. N. Z., Chong, M. S. K., Choolani, M. A., Chen, J., Antoniou, M. N., & Chan, J. K. Y. (2014) · PLoS ONE · doi:10.1371/journal.pone.0104805 · Cited by 24
“HSC-based gene therapy is gaining traction with a number of clinical trials targeting different conditions (X-SCID, ADA-SCID, ALD, CGD, Fanconi anemia, b-thalassemia) showing encouraging results [2,3,6,27-30] and which have implications for curative lifelong treatment.”
BackgroundAlternative options for DNA-based experimental therapy of β-thalassemia
Gambari, R. (2012) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2012.665047 · Cited by 30
“However, the unexpected observation of the expansion of clonal cells with the same gene insertion (the HMGA2 gene) suggests that a lentiviral vector can produce a growth advantage of selected cells [93], with a pattern reminiscent of the gene therapy trial for X-linked combined immuno deficiency disease (SCID) in whic…”
Rapid and Sensitive Assessment of Globin Chains for Gene and Cell Therapy of Hemoglobinopathies
Loucari, C. C., Patsali, P., van Dijk, T. B., Stephanou, C., Papasavva, P. L., Zanti, M., Kurita, R., Nakamura, Y., Christou, S., Sitarou, M., et al. (2018) · Human Gene Therapy Methods · doi:10.1089/hgtb.2017.190 · Cited by 23
“RP-HPLC data are commonly used in cell and gene therapy publications, but frequently source data are not shown at all or indicate technical shortcomings (such as sloping baselines).(35) Protocol optimization for RP-HPLC based on C4 column resin has resulted in sensitive detection of down to 0.”
MethodT-cell receptor gene-modified cells: past promises, present methodologies and future challenges
Rego, R. T., Morris, E. C., & Lowdell, M. W. (2019) · Cytotherapy · doi:10.1016/j.jcyt.2018.12.002 · Cited by 23
Pluripotent Stem Cell-Based Therapeutics for Muscular Dystrophies
Selvaraj, S., Kyba, M., & Perlingeiro, R. C. R. (2019) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2019.07.004 · Cited by 26
CRISPR/Cas9 technology: towards a new generation of improved CAR-T cells for anticancer therapies
Ureña-Bailén, G., Lamsfus‐Calle, A., Daniel-Moreno, A., Raju, J., Schlegel, P., Seitz, C. M., Atar, D., Antony, J. S., Handgretinger, R., & Mezger, M. (2019) · Briefings in Functional Genomics · doi:10.1093/bfgp/elz039 · Cited by 24
Genetic and epigenetic modification of human primary NK cells for enhanced antitumor activity
Kararoudi, M. N., Tullius, B. P., Chakravarti, N., Pomeroy, E. J., Moriarity, B. S., Béland, K., Colamartino, A., Haddad, É., Chu, Y., Cairo, M. S., et al. (2020) · Seminars in Hematology · doi:10.1053/j.seminhematol.2020.11.006 · Cited by 26
Breda, L., Ghiaccio, V., Tanaka, N., Jarocha, D. J., Ikawa, Y., Abdulmalik, O. Y., Dong, A., Casu, C., Raabe, T. D., Shan, X., et al. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2020.12.036 · Cited by 23
Self-citationHurdles to the Adoption of Gene Therapy as a Curative Option for Transfusion-Dependent Thalassemia
Thuret, I., Ruggeri, A., Angelucci, E., & Chabannon, C. (2022) · Stem Cells Translational Medicine · doi:10.1093/stcltm/szac007 · Cited by 25
Uchida, N., Evans, M., Hsieh, M. M., Bonifacino, A. C., Krouse, A. E., Metzger, M. E., Sellers, S. E., Dunbar, C. E., Donahue, R. E., & Tisdale, J. F. (2013) · Molecular Therapy — Nucleic Acids · doi:10.1038/mtna.2013.49 · Cited by 24
Hematopoietic Stem Cell Gene Therapy: Assessing the Relevance of Preclinical Models
Larochelle, A., & Dunbar, C. E. (2013) · Seminars in Hematology · doi:10.1053/j.seminhematol.2013.03.025 · Cited by 24
What can we learn from virus in designing nonviral gene vectors
Xu, C.-H., Sui, M., Tang, J., & Shen, Y. (2011) · Chinese Journal of Polymer Science · doi:10.1007/s10118-011-1047-5 · Cited by 25
Nègre, O., Fusil, F., Colomb, C., Roth, S. L., Gillet-Legrand, B., Henri, A., Beuzard, Y., Bushman, F. D., Leboulch, P., & Payen, E. (2011) · Blood · doi:10.1182/blood-2010-01-263582 · Cited by 25
Self-citationMouse models in hematopoietic stem cell gene therapy and genome editing
Radtke, S., Humbert, O., & Kiem, H. (2019) · Biochemical Pharmacology · doi:10.1016/j.bcp.2019.113692 · Cited by 22
Fañanas-Baquero, S., Bustamante, O. Q., Dever, D. P., Alberquilla, O., Sánchez‐Domínguez, R., Camarena, J., Ojeda-Pérez, I., Dessy-Rodríguez, M., Turk, R., Schubert, M. S., et al. (2021) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2021.05.001 · Cited by 23
Zakas, P. M., Cunningham, S. C., Doherty, A., van Dijk, E. B., Ibraheim, R., Yu, S., Mekonnen, B. D., Lang, B., English, E. J., Sun, G., et al. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.06.021 · Cited by 22
Cooper, A. R., Lill, G. R., Gschweng, E. H., & Kohn, D. B. (2014) · Nucleic Acids Research · doi:10.1093/nar/gku1312 · Cited by 24
Persons, D. A. (2010) · Nature · doi:10.1038/467277a · Cited by 22
Gene therapy using retrovirus vectors: vector development and biosafety at clinical trials
Knayo, D. O. I., & Takeuchi, Y. (2015) · Uirusu · doi:10.2222/jsv.65.27 · Cited by 23
Genome Editing Techniques and Their Therapeutic Applications
Calos, M. P. (2016) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.542 · Cited by 26
Treatment of β 654 ‐thalassaemia by TALEN s in a mouse model
Fang, Y., Cheng, Y., Lü, D., Gong, X., Yang, G., Gong, Z., Zhu, Y., Sang, X. M., Fan, S., Zhang, J., et al. (2018) · Cell Proliferation · doi:10.1111/cpr.12491 · Cited by 25
The gene therapy journey for hemophilia: are we there yet?
High, K. A. (2012) · Hematology · doi:10.1182/asheducation.v2012.1.375.3797885 · Cited by 23
Zhou, S., Ma, Z., Lu, T., Janke, L., Gray, J. T., & Sorrentino, B. P. (2013) · PLoS ONE · doi:10.1371/journal.pone.0062333 · Cited by 22
Nowrouzi, A., Cheung, W., Li, T., Zhang, X., Arens, A., Paruzynski, A., Waddington, S. N., Osejindu, E., Reja, S., Kalle, C. V., et al. (2013) · Molecular Therapy · doi:10.1038/mt.2012.224 · Cited by 24
Ramezani, A., Zweier, L., & Hawley, R. G. (2011) · Thrombosis and Haemostasis · doi:10.1160/th10-11-0725 · Cited by 22
Development of nuclease-mediated site-specific genome modification
Wirt, S. E., & Porteus, M. H. (2012) · Current Opinion in Immunology · doi:10.1016/j.coi.2012.08.005 · Cited by 24
Therapeutic gene editing strategies using CRISPR-Cas9 for the β-hemoglobinopathies
Papizan, J. B., Porter, S. N., Sharma, A., & Pruett‐Miller, S. M. (2020) · Journal of Biomedical Research · doi:10.7555/jbr.34.20200096 · Cited by 25
A Small Key for a Heavy Door: Genetic Therapies for the Treatment of Hemoglobinopathies
Zittersteijn, H. A., Harteveld, C. L., Klaver-Flores, S., Lankester, A. C., Hoeben, R. C., Staal, F. J. T., & Gonçalves, M. A. F. V. (2021) · Frontiers in Genome Editing · doi:10.3389/fgeed.2020.617780 · Cited by 24
“An initial β-thalassemia gene therapy course was tested in a transfusion-dependent βE/β0 patient using the Lentiglobin HPV569 vector (Malik et al., 2005; Cavazzana-Calvo et al., 2010) (Table 1).”
MethodEvaluation of diversity indices to estimate clonal dominance in gene therapy studies
Corre, G., & Galy, A. H. M. (2023) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2023.05.003 · Cited by 22
Delivery of Growth Factors to Enhance Bone Repair
Ball, J. R., Shelby, T., Hernandez, F., Mayfield, C. K., & Lieberman, J. R. (2023) · Bioengineering · doi:10.3390/bioengineering10111252 · Cited by 27
Moiani, A., Letort, G., Lizot, S., Chalumeau, A., Foray, C., Félix, T., Clerre, D. L., Temburni, S., Hong, P. W.-P., Leduc, S., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-49353-3 · Cited by 21
Fetal gene therapy: recent advances and current challenges
Mattar, C. N. Z., Choolani, M. A., Biswas, A., Waddington, S. N., & Chan, J. K. Y. (2011) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2011.585153 · Cited by 21
“An ex vivo gene therapy approach with autologous cells may be of benefit as demonstrated in multiple post-natal ex vivo gene therapy trials [105-110].”
BackgroundAdeno‐Associated Virus Vector–Based Gene Therapy for Monogenetic Metabolic Diseases of the Liver
Junge, N., Mingozzi, F., Ott, M., & Baumann, U. (2015) · Journal of Pediatric Gastroenterology and Nutrition · doi:10.1097/mpg.0000000000000703 · Cited by 23
Optimizing autologous cell grafts to improve stem cell gene therapy
Psatha, N., Karponi, G., & Yannaki, E. (2016) · Experimental Hematology · doi:10.1016/j.exphem.2016.04.007 · Cited by 22
“Although the last decade granted clinical GT with sound achievements, successful implementation of GT still faces major constraints including, in certain cases, limited efficacy due to suboptimal transduction efficiency or engraftment incompetence of the genemodified cells[6,12,13].”
BackgroundPractical considerations for chimeric antigen receptor design and delivery
Oldham, R. A. A., & Medin, J. A. (2017) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2017.1339687 · Cited by 22
“18 Studies in animals and humans report significantly less genotoxicity associated with LVs [151, 159, 160, 161, 162, 163, 164, 165], though there have been reports of deregulated gene expression cause by interference with splicing and polyadenylation [166, 167], and at least one clinical study found clonal dominance…”
BackgroundLabisch, J. J., Bollmann, F., Wolff, M. W., & Pflanz, K. B. (2020) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2020.12.004 · Cited by 22
Margolis, D. M., & Bushman, F. D. (2014) · Science · doi:10.1126/science.1257426 · Cited by 21
Self-citationApplication of genome editing technologies to the study and treatment of hematological disease
Pellagatti, A., Dolatshad, H., Yip, B. H., Valletta, S., & Boultwood, J. (2015) · Advances in Biological Regulation · doi:10.1016/j.jbior.2015.09.005 · Cited by 22
Eisenman, D., & Swindle, S. (2022) · Applied Biosafety · doi:10.1089/apb.2022.0022 · Cited by 21
Nogalska, A., Eerdeng, J., Akre, S., Vergel-Rodriguez, M., Lee, Y., Bramlett, C. S., Chowdhury, A. Y., Wang, B., Cess, C. G., Finley, S. D., et al. (2024) · Cellular and Molecular Immunology · doi:10.1038/s41423-024-01225-y · Cited by 21
“In some models, clonal expansion is thought to play an important role [1, 19] and is monitored in clinical settings as an indicator of leukemia genesis in elderly individuals [20 – 24].”
Seo, D. K., Kim, J. H., Min, J., Yoon, H. H., Shin, E. S., Kim, S. W., & Jeon, S. R. (2017) · Acta Neurochirurgica · doi:10.1007/s00701-017-3097-0 · Cited by 20
“Moreover, various clinical trials using lentivirus-mediated gene therapy have been introduced [8, 15, 29, 47].”
BackgroundAntony, J. S., Haque, A. K. M. A., Lamsfus‐Calle, A., Daniel-Moreno, A., Mezger, M., & Kormann, M. (2018) · Advances in Cell and Gene Therapy · doi:10.1002/acg2.10 · Cited by 21
“random integration loads (5-20 million/kg body weight), which raise a possible safety concern related to insertional mutagenesis.(4,5) Moreover, the random integration of viral vectors result in either low or very high transgene expression often without expression control of the cellular system.”
BackgroundEmerging Therapeutic Approaches for Diamond Blackfan Anemia
Aspesi, A., Borsotti, C., & Follenzi, A. (2018) · Current Gene Therapy · doi:10.2174/1566523218666181109124538 · Cited by 23
“Considerable progress has been also achieved in the gene therapy of β-thalassemia and sickle cell disease [44, 45].”
BackgroundToffoli, M., Smith, L., & Schapira, A. H. V. (2020) · Journal of Neurochemistry · doi:10.1111/jnc.14968 · Cited by 22
“…severe combined immunodeficiency, WiskottAldrich syndrome and adenosine deaminase deficiency have already been treated by infusion of autologous hematopoietic stem cells genetically treated ex vivo by the use of viral vectors (Aiuti et al., 2013; Cartier et al., 2009; Cavazzana-Calvo et al., 2010).”
BackgroundAli, G., Tariq, M. A., Shahid, K., Ahmad, F. J., & Akram, J. (2020) · Gene Therapy · doi:10.1038/s41434-020-0153-9 · Cited by 29
Psatha, N., Sgouramali, E., Gkountis, A., Siametis, A., Baliakas, P., Constantinou, V., Athanasiou, E., Arsenakis, M., Anagnostopoulos, Α., Papayannopoulou, T., et al. (2014) · Human Gene Therapy Methods · doi:10.1089/hgtb.2014.005 · Cited by 20
“, 2013), and thalassemia (Cavazzana-Calvo et al., 2010), have been cured during the last decade by stem cell gene therapy.”
Metadata
- Authors
- Cavazzana-Calvo, M., Payen, E., Negre, O., Wang, G., Hehir, K., Fusil, F., Down, J., Denaro, M., Brady, T., Westerman, K., Cavallesco, R., Gillet-Legrand, B., Caccavelli, L., Sgarra, R., Maouche-Chrétien, L., Bernaudin, F., Girot, R., Dorazio, R., Mulder, G.-J., Polack, A., Bank, A., Soulier, J., Larghero, J., Kabbara, N., Dalle, B., Gourmel, B., Socie, G., Chrétien, S., Cartier, N., Aubourg, P., Fischer, A., Cornetta, K., Galacteros, F., Beuzard, Y., Gluckman, E., Bushman, F., Hacein-Bey-Abina, S., & Leboulch, P.
- Affiliations
- Inserm (FR)
- University of Pennsylvania (US)
- Brigham and Women's Hospital (US)
- University of Trieste (IT)
- Hôpital Intercommunal de Créteil (FR)
- Hôpital Tenon (FR)
- Columbia University Irving Medical Center (US)
- Assistance Publique – Hôpitaux de Paris (FR)
- Indiana University Indianapolis (US)
- Corresponding author
- Leboulch, Philippe
- ORCID
- Venue
- Nature
- Published
- 2010-09
- Volume
- 467
- Issue
- 7313
- Pages
- 318-322
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC3355472
- OpenAlex
- W2136274459
- Cited by
- 1,276
- References
- 32
- Citations by year
- 2026: 14 · 2025: 45 · 2024: 46 · 2023: 53 · 2022: 64 · 2021: 75 · 2020: 76 · 2019: 84 · 2018: 79 · 2017: 97 · 2016: 94 · 2015: 99 · 2014: 94 · 2013: 116 · 2012: 106
- FWCI
- 63.92
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- HAL (submittedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- ArTS Archivio della ricerca di Trieste (University of Trieste https://www.units.it/) (submittedVersion)
- IUScholarWorks (Indiana University) (submittedVersion)
- Funders
- National Institutes of Health
- National Heart, Lung, and Blood Institute (R01HL090921, HL090921)
- National Institute of Allergy and Infectious Diseases (AI52845, R01AI082020, R01AI052845, AI082020)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Health Sciences › Medicine › Genetics (clinical) › Hemoglobinopathies and Related Disorders
- Health Sciences › Medicine › Genetics (clinical) › Lysosomal Storage Disorders Research
- Keywords
- beta-thalassemia, gene therapy, lentiviral vectors, transfusion independence, HMGA2, leukemia risk, hemoglobinopathies, sickle cell disease, hematopoietic stem cells, alternative splicing, hemoglobin
- MeSH terms
- Adolescent, Blood Cells, Blood Transfusion, Bone Marrow Cells, Child, Preschool, Clone Cells, Genetic Vectors, Homeostasis, Humans, Male, Organ Specificity, RNA, Messenger, Time Factors, Genetic Therapy, Transcriptional Activation, Gene Expression, Lentivirus, beta-Thalassemia, HMGA2 Protein, MicroRNAs, beta-Globins, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.